Kiadis Pharma announces that three abstracts related to its K-NK-cell therapy platform have been accepted at the ASCO 2020 Virtual Annual Meeting

Amsterdam, The Netherlands, May 13, 2020 – Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces three abstracts supporting the potential of the Company's K-NK cell therapy program to treat relapsed/refractory acute myeloid leukemia (R/R ML) have been accepted at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting taking place May 29 – 31, 2020.

The ASCO abstracts are now available at https://meetings.asco.org/am/virtual-format. Details of the presentations are as follows:

· **Abstract #3025** has been accepted as a poster and presents clinical data of a subset of R/R AML patients with CNS disease treated with FC21-NK cells in a phase I/II study (NCT02809092).

Abstract Details
Title: CD56bright/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML.
Presenter: Lucia Silla
Session title: Developmental Therapeutics—Immunotherapy

· **Abstract #TPS7562** is a 'trials in progress' poster summarizing how off-the-shelf FC21-NK is investigated to treat R/R AML and MDS patients (NCT04220684). This study is sponsored by Ohio State University and supported by Kiadis.

Abstract Details
Title: A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells for Relapse/Refractory Acute Myeloid Leukemia
Presenter: Sumi Vasu
Session title: Trials in Progress poster #335

· **Abstract e15018** was accepted for publication only and contains pre-clinical data that show CD38 knock-out of FC21-NK cells limits NK cell fratricide and enhances the overall activity against Multiple Myeloma cells in presence of an anti-CD38 antibody.

Abstract Details
Title: Impact of CD38 Knockout in NK Cells on Daratumumab-mediated Cytotoxicity and Cellular Metabolism.
Presenter: Yuya Nagai
Session title: Online publication only available on May 13, 2020, 5:00 p.m. ET

Kiadis Pharma contacts

Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com

Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com

About Kiadis Pharma's K-NK-Cell Therapies
Kiadis Pharma's NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.

The Company's NK-cell PM21 particle technology enables improved *ex vivo* expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma's proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.

About Kiadis Pharma
Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Kiadis Pharma kondigt drie presentaties over K-NK-celtherapieplatform op ASCO 2020

Amsterdam, 13 mei 2020 – Kiadis Pharma N.V. ('Kiadis Pharma' of de 'Onderneming') (Euronext Amsterdam en Brussel: KDS), gaat drie presentatie houden op de (dit jaar virtuele) bijeenkomst van de American Society of Clinical Oncology (ASCO), van 29 mei tot 31 mei 2 2020. De drie presentaties zijn gericht op het potentieel van het KNK-celtherapieprogramma voor de behandeling van terugkerende acute myeloïde leukemie (R/R ML).

De volledige ASCO presentaties zijn beschikbaar op www.asco.org. Hier volgen nadere gegevens van de presentaties:

· **Abstract 3025** is geaccepteerd als posterpresentatie en toont de klinische gegevens van een subset van R/R AML-patiënten met CNS-ziekte, die behandeld zijn met FC21-NK cellen in een fase I/II-studie (NCT02809092).

Details van de presentatie
Titel: 'CD56bright/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML' (CD56bright/CD16bright NK-cel adoptie-immunotherapie bij patiënten met een gelijktijdige CNS-aandoening en teruggekeerd of refractair (R/R) AML).
Presentator: Lucia Silla
Sessietitel: Developmental Therapeutics—Immunotherapy (Ontwikkelingstherapie - Immunotherapie)

· **Abstract TPS7562** is een posterpresentatie in de categorie 'lopende studies' waarin wordt samengevat hoe gebruiksklare FC21-NK wordt onderzocht voor de behandeling van R/R AML- en MDS-patiënten (NCT04220684). Deze studie wordt uitgevoerd door Ohio State University en ondersteund door Kiadis.

Details van de presentatie
Titel: 'A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells for Relapse/Refractory Acute Myeloid Leukemia' (Een fase I-klinische studie naar de veiligheid van IL-21-expansie, gebruiksklare, natural killer-cellen voor teruggekeerde of refractair acute myeloïde leukemie).
Presentator: Sumi Vasu
Sessietitel: Trials in Progress poster #335 (Lopende studies posterpresentatie 335)

· **Abstract** #e15018 werd geaccepteerd voor publicatie en bevat preklinische gegevens die tonen dat een CD38 knock-out van FC21-NK-cellen de NK cel fratricide beperkt en de algemene activiteit tegen Multipel Myeloom cellen in aanwezigheid van een anti-CD38 antilichaam verbetert.

Details van de presentatie
Titel: 'Impact of CD38 Knockout in NK Cells on Daratumumab-mediated Cytotoxicity and Cellular Metabolism' (Impact van CD38-knockout in NK-cellen op met Daratumumab gemedieerde cytotoxiciteit en cellulair metabolisme).
Presentator: Yuya Nagai
Sessietitel: Online publicatie beschikbaar op 13 mei 2020, 17:00 EST

Voor meer informatie:

Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305

Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144

m.cimino@kiadis.com

David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com

Over de K-NK-celtherapie van Kiadis Pharma

Het K-NK-platform van Kiadis Pharma is ontworpen om krachtige NK-cellen te leveren om patiënten te kunnen helpen zonder dat genetische manipulatie nodig is. De programma's van Kiadis Pharma bestaan uit direct beschikbare en voor elke patiënt apart gemaakte donor-NK-celtherapieproducten voor de behandeling van hematologische en solide tumoren als aanvullende en zelfstandige therapieën.

De PM21-deeltjestechnologie maakt verbeterde ex vivo-expansie en activering van cytotoxische NK-cellen mogelijk, waardoor meerdere infusies met hoge doses kunnen worden toegediend. Het eigen platform voor direct beschikbare NK-cellen van Kiadis Pharma is gebaseerd op NK-cellen van unieke, universele donoren en maakt het mogelijk om NK-celtherapieproducten snel en goedkoop beschikbaar te maken voor een brede patiëntpopulatie in een groot aantal indicaties.

Kiadis Pharma ontwikkelt K-NK002 als een aanvullende immunotherapie naast HSCT, en K-NK003 voor de behandeling van terugkerende of refractaire acute myeloïde leukemie. Daarnaast heeft Kiadis Pharma preklinische programma's waarin NK-celtherapie voor de behandeling van solide tumoren wordt geëvalueerd.

Over Kiadis Pharma

Kiadis Pharma is opgericht in 1997 en ontwikkeld zich tot een volledig geïntegreerd biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van innovatieve therapieën voor patiënten met levensbedreigende ziekten. Het hoofdkantoor is gevestigd in Amsterdam, en Kiadis Pharma is tevens actief in de Verenigde Staten. Het bedrijf heeft een revolutionaire benadering, waarbij de natuurlijke kracht van de mens en ons collectieve immuunsysteem benut worden.

Kiadis Pharma is sinds 2 juli 2015 onder het symbool KDS genoteerd aan de beurzen van Euronext Amsterdam en Euronext Brussels. Meer informatie vindt u op www.kiadis.com.

Dit persbericht vormt een vertaling van het gelijktijdig gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.